Ixazomib CAS No.1072833-77-2 Pharmaceutical Intermediates

 1. Cancer Treatment Efficacy: Ixazomib has demonstrated significant efficacy in patients with multiple myeloma in clinical trials, especially when used in combination with other drugs such as lenalidomide and dexamethasone. Ixazomib's ability to target the proteasome pathway provides a new approach to cancer treatment, bringing hope to patients with limited treatment options.

 2. Oral administration: A major advantage of ixazomib is its oral bioavailability, which makes administration more convenient compared to traditional intravenous therapy. This feature not only improves patient compliance, but also reduces the burden on medical institutions, making it a practical option for outpatient treatment.

 3. High Purity and Quality: As a manufacturer integrating production and trading, we prioritize quality control throughout the entire production process. Our Ixazomib is produced under strict guidelines to ensure high purity levels that meet or exceed industry standards. This commitment to quality is critical for pharmaceutical companies seeking reliable and effective ingredients.

 4. Competitive Pricing: By optimizing our production processes and leveraging our manufacturing capabilities, we are able to offer Ixazomib at a competitive price. This affordable price makes it an attractive option for pharmaceutical companies looking to enhance their product portfolio without compromising quality.

 5. Reliable supply chain: We adopt an integrated production and trading approach to ensure a reliable supply chain, enabling us to meet customer needs in a timely manner. We understand the importance of timely delivery in the pharmaceutical industry and are committed to providing consistent and reliable services to our partners.

The molecular formula of ixazomib is C14H19BCl2N2O4, and the molecular weight is approximately 361.03 g/mol. It is a White to light yellow powde that is stable under normal storage conditions. The compound is soluble in organic solvents such as DMSO and methanol, and has limited solubility in water. Its melting point is typically around 150-155°C, which ensures stability during handling and storage.

 The compound has good solubility and stability, is suitable for oral administration, is easy to administer, and can improve patient compliance. In addition, the pharmacokinetic properties of ixazomib support its combination with other therapeutic agents to maximize its efficacy in the treatment of complex malignancies.

In summary, Ixazomib represents a significant advancement in the treatment of multiple myeloma and other hematologic malignancies. Its unique physical and chemical properties, combined with its proven efficacy and our commitment to quality, make it an ideal choice for pharmaceutical companies seeking innovative solutions. Partner with us to explore the potential of Ixazomib and take your drug products to new heights. Together, we can make a meaningful impact in the fight against cancer.